Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2007 Apr 4.
Published in final edited form as: Epidemiology. 2005 May;16(3):346–354. doi: 10.1097/01.ede.0000158742.11877.99

Influence of Body Size and Body Fat Distribution on Risk of Uterine Leiomyomata in U.S. Black Women

Lauren A Wise *,, Julie R Palmer , Donna Spiegelman *,, Bernard L Harlow *,§, Elizabeth A Stewart ||, Lucile L Adams-Campbell , Lynn Rosenberg
PMCID: PMC1847589  NIHMSID: NIHMS19329  PMID: 15824551

Abstract

Background

Uterine leiomyomata are a major source of morbidity in black women. We prospectively investigated the risk of self-reported uterine leiomyomata in relation to body mass index (BMI), weight change, height, waist and hip circumferences, and waist-to-hip ratio in a large cohort of U.S black women.

Methods

Data were derived from the Black Women’s Health Study, a U.S. prospective cohort study of black women who complete biannual mailed health questionnaires. From 1997 through 2001, we followed 21,506 premenopausal women with intact uteri and no prior diagnosis of uterine leiomyomata. Cox regression models were used to estimate incidence rate ratios (IRRs) and 95% confidence intervals (CIs).

Results

After 70,345 person-years of follow up, 2146 new cases of uterine leiomyomata confirmed by ultrasound (n = 1885) or hysterectomy (n = 261) were self-reported. Compared with the thinnest women (BMI <20.0 kg/m2), the multivariate IRRs for women with BMIs of 20.0–22.4, 22.5–24.9, 25.0–27.4, 27.5–29.9, 30.0–32.4, and 32.5= kg/m2 were 1.34 (95% CI = 1.02–1.75), 1.39 (1.07–1.81), 1.45 (1.12–1.89), 1.47 (1.11–1.93), 1.36 (1.02–1.80), and 1.21 (0.93–1.58), respectively. IRRs were larger among parous women. Weight gain since age 18 was positively associated with risk, but only among parous women. No other anthropometric measures were associated with risk.

Conclusions

BMI and weight gain exhibited a complex relation with risk of uterine leiomyomata in the Black Women’s Health Study. The BMI association was inverse J-shaped and findings were stronger in parous women. Weight gain was positively associated with risk among parous women only.


Uterine leiomyomata (fibroids) are benign neoplasms arising from smooth muscle of the uterus and are the leading cause of hysterectomy in the United States.1 Symptoms can include heavy menstrual bleeding, pelvic pain, and reproductive dysfunction.2,3 Black women have 2 to 3 times the risk of white women,3,4 as well as earlier ages at first diagnosis24 and more numerous and symptomatic tumors at the time of diagnosis.2,3

Ovarian hormones are believed to play a key role in the etiology of uterine leiomyomata.5 Body mass index (BMI = weight[kg]/height[m]2) is a measure of absolute body fat6 and may influence the risk of uterine leiomyomata through changes in steroid hormone metabolism and bioavailability.7 Studies in premenopausal women have consistently documented an inverse association between BMI and circulating levels of sex hormone-binding globulin.810 Decreases in sex hormone-binding globulin may increase the proportion of free estrogen or the fraction available for biologic activity.8 Obesity is associated with diminished 2-hydroxylation of estrone to catechol estrogens and increased 16-alpha-hydroxylation of estrone to estriol, thereby producing estrogens with greater uterotropic activity.11,12

Epidemiologic studies of predominantly white populations show mixed results with respect to the association between BMI and uterine leiomyomata.1317 Although some studies show a positive association13,15,16 or an inverse J-shaped association,14,17 others show no association.1820 One of these studies15 also found a positive association with adult weight gain, but not with height or BMI at age 18. There is evidence that premenopausal black women may have higher ovarian hormone levels than white women21,22 and that estradiol levels decrease with increasing BMI in black women, but not white women.23 Given these observations, the influence of BMI on risk of uterine leiomyomata may differ between black and white women.

The relation of uterine leiomyomata to body fat distribution, as measured by waist circumference or waist-to-hip ratio,6 has not been evaluated. Independent of BMI, central obesity (excess fat in the upper trunk region) is associated with hormonal and metabolic changes in premenopausal women,24 including altered estrogen metabolism,24 insulin resistance and hyperinsulinemia,25,26 and decreases in sex hormone-binding globulin levels.9,24 Insulin, which is itself a mitogenic agent,5 is associated with downregulation of sex hormone-binding globulin26 and upregulation of insulin-like growth factor-1 and epidermal growth factor5; these agents could influence tumor development through direct promotion of myometrial smooth muscle cell proliferation or enhanced ovarian hormone secretion.5,7

In the United States, the prevalence of obesity (BMI ≥30 kg/m2) is nearly twice as high in black women as in white women.27 If obesity is related to an increased risk of uterine leiomyomata, obesity might explain a large fraction of the disease burden among black women. We prospectively investigated the influence of BMI and other anthropometric measures—weight gain, height, waist circumference, and waist-to-hip ratio—on risk of uterine leiomyomata in pre-menopausal U.S. black women.

METHODS

Study Population

The Black Women’s Health Study is an ongoing prospective cohort study of risk factors for major illnesses in U.S. black women. Approximately 59,000 black women age 21 to 69 years were enrolled through questionnaires mailed mainly to subscribers of Essence magazine and have been followed since March 1995.28 The baseline questionnaire elicited information on demographic and behavioral characteristics, reproductive and contraceptive histories, healthcare utilization, and medical conditions. Updated information is obtained by mailed questionnaire every 2 years and more than 80% of the cohort has completed a questionnaire in each follow-up cycle. Respondents represent various geographic regions of the United States, with the majority residing in California, New York, Illinois, Michigan, Georgia, and New Jersey.

Follow up for the present analysis began in 1997, the start of the second questionnaire cycle, because data on method of confirmation for uterine leiomyomata were first obtained on the 1999 questionnaire. Of the 53,322 women who completed the 1997 questionnaire, we restricted the analytic sample to premenopausal women with intact uteri (n = 36,618), because uterine leiomyomata are rare after menopause.4,13,17 We excluded women who reported a diagnosis of leiomyomata before 1997 (n = 10,449), who did not complete a 1999 or a 2001 follow-up questionnaire (n = 2307), “cases” with no information about year of diagnosis (n = 100) or confirmation method (n = 207), and women with potentially unrepresentative anthropometric measurements (those who were currently pregnant at the time they completed the 1995 [n = 566] or 1997 [n = 392] questionnaires; who reported gastric surgery for weight loss [n = 55]; or who had implausible data on current weight, weight at age 18, height, or other covariates [n = 1059]). After these exclusions, 21,506 women remained and were followed over the subsequent 4 years. Separate analyses were conducted for women with complete data on waist and hip circumference (n = 17,876); these participants had a lower median BMI than those with incomplete data (26.0 vs. 27.3 kg/m2).

Assessment of Uterine Leiomyomata

Transvaginal ultrasound is the clinical standard used to confirm diagnoses of uterine leiomyomata. Although histologic evidence is the gold standard,29 histologically confirmed cases represent only 10% to 30% of cases for whom ultrasound evidence is available.4,7 Studies limited to histologic cases may spuriously identify risk factors associated with large tumor size, symptoms, or treatment preference.7 To minimize the potential for bias, we expanded our outcome definition to include confirmation by ultrasound and/or hysterectomy. This definition was previously used by the Nurses’ Health Study II, a prospective study with similar methodology.4,15 Ultrasound has high sensitivity (99%) and specificity (91%) relative to histologic evidence.29

On the 1999 and 2001 follow-up questionnaires, women were asked if they had been diagnosed with “fibroids” in the previous 2-year interval and, if “yes,” the calendar year in which they were first diagnosed and the method of confirmation: “pelvic examination” or “ultrasound/hysterectomy.” A diagnosis was classified as “hysterectomy-confirmed” if the woman reported hysterectomy on the same questionnaire.

Incident cases were defined as women who self-reported on the 1999 or 2001 questionnaire a first diagnosis of “fibroids” confirmed by ultrasound or hysterectomy. The index date for each case was defined as the midpoint of the reported calendar year in which the diagnosis was confirmed. Women with diagnoses confirmed only by pelvic examination (n = 387) were treated as noncases in primary analyses because their diagnoses may have represented other pathology.15,29 As the diagnosis may have influenced a change in lifestyle factors, their exposure information was not updated beyond the time of diagnosis.

We assessed the accuracy of self-reported uterine leiomyomata in a random sample of 248 cases confirmed by ultrasound or hysterectomy. These women were mailed supplemental questionnaires regarding symptoms, diagnostic confirmation, and treatment, and were asked for permission to review their medical records. We obtained medical records for 127 of the 128 women who gave us permission, and we confirmed the self-report in 122 (96%). The proportion of cases reporting an initial diagnosis confirmed by ultrasound varied little with BMI, ranging from 100% among the leaner women (BMI <20 kg/m2) to 96% among the obese women (BMI ≥30 kg/m2). Among the 188 (76%) cases who completed the supplemental questionnaire, 71% reported the presence of symptoms before diagnosis; this proportion was similar across categories of BMI.

Assessment of Body Size, Body Fat Distribution, and Other Covariates

In 1995, we collected information on self-reported height (feet and inches), current weight (pounds), weight at age 18 (pounds), waist circumference (inches) at the level of the umbilicus, and hip circumference (inches) at its widest location. Current weight was updated every 2 years by follow-up questionnaire. BMI was calculated as weight (kg) divided by height squared (m2).

In 2001, Howard University investigators conducted a validation study of anthropometric measures among Black Women’s Health Study participants from the Washington, DC, area. The first 115 participants who responded to mailed invitations were enrolled. The Spearman correlation between self-reported weight (mean = 176 lbs) and technician-measured weight (mean = 181 lbs) was 0.97. The coefficient between self-reported height (mean = 64.4 in) and technician-measured height (mean = 64.0 in) was 0.93. Spearman correlations for self-reported versus technician-measured waist circumference, hip circumference, and waist-to-hip ratio were 0.75, 0.74, and 0.54, respectively. Self-reported waist, hip, and waist-to-hip ratio measurements were, on average, 4.7 inches, 3.1 inches, and 0.05 units lower than technician measurements.

Data on parity, age at each birth, oral contraceptives, smoking, and alcohol consumption were obtained on the baseline and follow-up questionnaires, and were treated as time-dependent variables in the analysis, as were BMI and weight gain.

Data Analysis

Each participant contributed person-time from March 1997 until the diagnosis of uterine leiomyomata, menopause, death, loss to follow up, or March 2001 (end of follow up), whichever came first. Incidence rates (IRs) in each category of the exposure variable were computed by dividing the number of incident cases in that category by the person-time in that category. We used multivariate Cox regression to estimate incidence rate ratios (IRRs) and 95% confidence intervals (CIs) for anthropometric variables of interest. To control for age, calendar time, and any 2-way interactions between these 2 time scales, we stratified our analyses jointly by baseline age in 1-year intervals and calendar year of the current questionnaire cycle.

A covariate was included in multivariate analyses if the literature supported its role as a confounder, or if adding it to a model containing all other risk factors for uterine leiomyomata changed the exposure IRR by 10% or more.30 Based on these criteria, we controlled for age at menarche, parity, age at first birth, years since last birth, oral contraceptive use, smoking, alcohol consumption, education, and geographic region.

Because parous women have a lower risk of uterine leiomyomata than nulliparous women,7,31 and are more likely to gain weight32,33 and have central obesity,33 we stratified the analyses by parity status. To examine whether the main associations were modified by parity or other risk factors, we conducted likelihood ratio tests that compared models with and without crossproduct terms between anthropometric variables (categorical) and selected covariates. Departures from the proportional hazards assumption (ie, effect modification by age and time) were tested by the likelihood ratio test comparing models with and without crossproduct terms between anthropometric variables and both time period (1997–1999 vs. 1999–2001) and age (<35 vs. 35+).

RESULTS

At the start of follow up (1997), 29% of the cohort was overweight (BMI = 25–29 kg/m2) and 30% was obese (BMI ≥30 kg/m2) according to World Health Organization standards34 (Table 1). Current BMI was positively related to BMI at age 18 years, waist circumference, hip circumference, parity, years since last birth, and energy intake, and inversely related to height, age at menarche, age at first birth, smoking, alcohol intake, and vigorous physical activity. Women living in the West were less likely than those living in other geographic regions to be overweight. Results from the Black Women’s Health Study regarding risk of uterine leiomyomata in relation to age,35 reproductive factors,31 and alcohol, caffeine, and tobacco consumption36 have been published elsewhere.

TABLE 1.

Characteristics of 21,506 Premenopausal Women According to Body Mass Index (kg/m2): the Black Women’s Health Study, 1997*

Body Mass Index
Characteristic <20.0 (n = 1330) 20.0–24.9 (n = 7454) 25.0–29.9 (n = 6336) 30.0+ (n = 6386)
BMI (kg/m2); mean 18.9 22.7 27.3 36.4
BMI at age 18 yr (kg/m2); mean 17.8 19.8 21.5 25.4
Height (1995) (in); mean 65.6 65.1 65.1 64.9
Waist circumference (1995) (in); mean 25.8 28.2 31.5 36.9
Hip circumference (1995) (in); mean 34.2 37.0 40.1 45.2
Energy intake (1995) (kcal/d); mean 1540 1450 1522 1664
Age at menarche (yr); mean§ 13.1 12.6 12.3 12.0
Age at first birth (yr); mean§ 23.8 23.5 22.9 22.4
Time since last birth (yr); mean§ 10.1 10.4 10.5 11.0
Age (yr); %
 <30 45 32 23 23
 30–39 43 45 45 44
 40+ 12 23 32 33
Parous; % 51 54 58 58
Geographic region of residence (1995); %
 Northeast 30 28 28 29
 West 21 21 18 15
 Midwest 20 21 23 25
 South 29 30 31 31
Education (1995) (yrs); %
 ≤ 12 11 10 14 17
 13–16 66 65 65 65
 17+ 23 25 21 18
Papanicolaou smear since 1995; % 89 92 91 88
Oral contraceptive use; %
 Current user 23 27 24 18
 Former user 56 56 58 60
Cigarette smoking; %
 Current smoker 17 13 14 15
 Former smoker 9 12 14 16
Current alcohol intake (1+ drinks/wk); % 27 29 29 25
Vigorous physical activity; %
 None 41 31 36 49
 <5 h/wk 48 54 53 45
 5+ h/wk 11 15 11 6
*

Data from 1997 (start of follow up) unless otherwise noted. Characteristics (with exception of age) are standardized to age distribution of women free of uterine leiomyomata at the start of follow up.

Limited to 17,876 women with complete data on waist and hip circumference.

Limited to 20,020 women with complete data on energy intake derived from a self-administered 68-item Block food frequency questionnaire.

§

Limited to 12,022 parous women.

During 70,345 person-years of follow up, 2146 new cases of uterine leiomyomata confirmed by ultrasound (n = 1885) or hysterectomy (n = 261) were self-reported. Compared with BMI <20.0 kg/m2, multivariate IRRs were elevated in all categories of BMI and ranged from 1.21 to 1.47 (Table 2). IRRs were larger among parous than nulliparous women (P value, test for interaction = 0.002). Crude incidence rates were higher in nulliparous women than in parous women, but only among women with normal or low BMI (Table 2). Associations in both groups were inverse J-shaped, although the peak incidence in risk differed: BMI = 27.5–29.9 kg/m2 in parous women versus BMI = 22.5–24.9 kg/m2 in nulliparous women. At the start of follow up, obese nulliparous women could have been more likely to have ovulatory infertility37 and less likely to have incident tumors detected by pregnancy ultrasound than lean nulliparous women. However, the same pattern of risk emerged after the exclusion of nulliparous women who reported infertility in 1995 or who reported a subsequent livebirth within the same 2-year interval as their diagnosis.

TABLE 2.

Incidence Rates (IRs) per 1000 Person-Years and Incidence Rate Ratios (IRRs) for Uterine Leiomyomata Confirmed by Ultrasound or Hysterectomy According to Measures of Body Size and Body Fat Distribution

All Women
Parous Women
Nulliparous Women
Anthropometric Variable No. of Cases Person-Years Crude IR Multivariate IRR (95% CI)* No. of Cases Crude IR Multivariate IRR (95% CI)* No. of Cases Crude IR Multivariate IRR (95% CI)* P Value, Test for Interaction
BMI, current (kg/m2) 0.002
 <20.0 80 4033 19.8 1.00 27 16.1 1.00 53 22.5 1.00
 20.0–22.4 290 10,297 28.2 1.34 (1.02–1.75) 109 22.3 1.26 (0.78–2.01) 181 33.5 1.46 (1.04–2.04)
 22.5–24.9 419 13,297 31.5 1.39 (1.07–1.81) 192 26.3 1.41 (0.90–2.22) 227 37.8 1.46 (1.04–2.03)
 25.0–27.4 423 12,606 33.6 1.45 (1.12–1.89) 237 30.9 1.66 (1.06–2.59) 186 37.7 1.38 (0.98–1.93)
 27.5–29.9 267 8085 33.0 1.47 (1.11–1.93) 167 33.7 1.81 (1.15–2.86) 100 31.9 1.23 (0.85–1.77)
 30.0–32.4 218 6778 32.2 1.36 (1.02–1.80) 129 31.3 1.70 (1.07–2.70) 89 33.4 1.14 (0.78–1.66)
 32.5+ 449 15,250 29.4 1.21 (0.93–1.58) 269 30.2 1.48 (0.95–2.32) 180 28.4 1.04 (0.74–1.47)
BMI at age 18 (kg/m2) 0.98
 <18.5 386 12,500 30.9 1.00 220 28.7 1.00 166 34.4 1.00
 18.5–19.9 421 13,877 30.3 1.02 (0.88–1.18) 230 27.9 1.06 (0.87–1.29) 191 33.9 0.98 (0.78–1.23)
 20.0–22.4 693 21,104 32.8 1.08 (0.95–1.24) 366 30.4 1.14 (0.95–1.37) 327 36.0 1.01 (0.82–1.24)
 22.5–24.9 341 10,899 31.3 1.02 (0.87–1.20) 175 28.9 1.07 (0.86–1.33) 166 34.3 0.98 (0.77–1.24)
 25.0–27.4 154 5884 26.2 0.90 (0.73–1.09) 79 26.8 1.02 (0.77–1.35) 75 25.6 0.78 (0.58–1.04)
 27.5–29.9 66 2469 26.7 0.88 (0.66–1.16) 30 25.9 0.94 (0.61–1.43) 36 27.5 0.82 (0.56–1.21)
 30.0+ 85 3613 23.5 0.81 (0.62–1.04) 30 21.5 0.86 (0.57–1.29) 55 24.8 0.76 (0.54–1.05)
Weight gain since age 18 (kg) <0.001
 <5 325 12,900 28.2 1.00 104 19.8 1.00 221 28.9 1.00
 5–9 312 10,994 28.4 1.10 (0.93–1.30) 120 22.7 1.21 (0.90–1.61) 192 33.6 1.04 (0.85–1.29)
 10–14 372 12,021 30.9 1.13 (0.97–1.33) 183 26.9 1.44 (1.10–1.88) 189 36.3 1.01 (0.81–1.25)
 15–24 595 18,016 33.0 1.18 (1.01–1.36) 356 31.0 1.45 (1.13–1.86) 239 36.6 1.05 (0.86–1.28)
 25+ 542 16,414 33.0 1.10 (0.95–1.29) 367 34.4 1.54 (1.21–1.98) 175 30.5 0.81 (0.65–1.00)
Height (feet and inches) 0.95
 ≤5′ 2″ 368 12,709 29.0 1.00 199 26.6 1.00 169 32.4 1.00
 5′ 3″–5′ 4″ 539 17,721 30.4 1.04 (0.90–1.19) 287 28.2 1.06 (0.87–1.29) 252 33.4 1.02 (0.83–1.26)
 5′ 5″–5′ 6″ 620 18,872 32.9 1.17 (1.02–1.34) 335 31.0 1.23 (1.02–1.48) 285 35.3 1.10 (0.89–1.34)
 5′ 7″–5′ 8″ 385 13,397 28.7 1.04 (0.89–1.21) 201 27.8 1.14 (0.92–1.41) 184 29.9 0.94 (0.75–1.18)
 5′ 9″+ 234 7647 30.6 1.08 (0.90–1.29) 108 28.5 1.17 (0.90–1.50) 126 32.7 1.01 (0.79–1.30)
Waist circumference (inches)§ 0.10
 <27 284 10,317 27.5 1.00 115 24.3 1.00 169 30.3 1.00
 27–29 452 14,146 32.0 1.08 (0.92–1.28) 193 26.8 1.00 (0.77–1.29) 259 37.3 1.16 (0.93–1.45)
 30–32 403 12,951 31.1 1.01 (0.84–1.21) 237 30.3 1.02 (0.78–1.33) 166 32.4 1.01 (0.78–1.31)
 33–35 286 8182 35.0 1.16 (0.94–1.43) 171 33.7 1.14 (0.85–1.52) 115 37.0 1.21 (0.89–1.66)
 36+ 377 12,938 29.1 0.97 (0.77–1.21) 226 28.9 0.97 (0.71–1.33) 151 29.6 0.99 (0.71–1.39)
Hip circumference (inches)§ 0.15
 <36 278 10,226 27.2 1.00 120 23.8 1.00 158 30.5 1.00
 36–37 315 10,198 30.9 1.11 (0.93–1.32) 147 27.2 1.18 (0.90–1.53) 168 35.1 1.04 (0.82–1.32)
 38–40 474 14,869 31.9 1.04 (0.87–1.24) 257 29.9 1.14 (0.88–1.47) 217 34.6 0.96 (0.75–1.22)
 41–44 408 12,779 31.9 1.04 (0.85–1.26) 236 30.7 1.08 (0.82–1.43) 172 33.8 1.01 (0.76–1.34)
 45+ 327 10,463 31.3 1.10 (0.88–1.38) 182 30.7 1.23 (0.90–1.67) 145 32.0 0.97 (0.69–1.36)
Waist-to-hip ratio§ 0.50
 <0.71 349 11,838 29.5 1.00 153 25.5 1.00 196 33.6 1.00
 0.71–0.75 375 11,611 32.3 1.07 (0.92–1.25) 187 30.9 1.12 (0.89–1.42) 188 33.8 1.02 (0.82–1.27)
 0.76–0.79 385 11,993 32.1 1.11 (0.95–1.30) 198 29.6 1.09 (0.87–1.37) 187 35.2 1.12 (0.90–1.39)
 0.80–0.85 368 11,521 31.9 1.12 (0.95–1.31) 217 32.3 1.23 (0.98–1.54) 151 31.6 1.03 (0.81–1.30)
 0.86+ 325 11,571 28.1 0.98 (0.83–1.16) 187 25.9 0.93 (0.73–1.18) 138 31.7 1.10 (0.86–1.41)
*

Adjusted for age (1-yr intervals), time period (1997–1999 vs. 1999–2001), age at menarche (years), parity (number of births), age at first birth (years), years since last birth (linear term + 2 spline terms), ever use of oral contraceptives, education (≤12, 13–15, 16, 17+), living in the West, current alcohol consumption (<1, 1–6, 7+ per week), and smoking (never, former, current). Models of waist, hip, and waist-to-hip ratio measures are further adjusted for BMI in 1995 (<20, 20–24, 25–29, 30+).

Likelihood ratio test comparing models with and without categorical anthropometric variable by parity interaction terms.

Reference category.

§

Limited to 17,876 women with complete data on waist and hip circumference in 1995.

Multivariate IRRs for BMI at age 18 were not notably different from 1.0 and did not vary appreciably by parity (Table 2). A positive association between weight gain since age 18 and uterine leiomyomata was evident among parous but not nulliparous women (P value, test for interaction <0.001). Among parous women, the multivariate IRR comparing weight gain of 25+ to <5 kg was 1.54 (95% CI = 1.21–1.98) and a positive monotonic trend was observed. Crude incidence rates were notably higher among nulliparous women than among parous women, but only in the lowest categories of weight gain. Adult height was not associated with risk.

None of the body fat distribution measures was independently associated with risk of uterine leiomyomata overall or among parity subgroups (Table 2). Findings remained unchanged when we controlled for height, BMI at age 18, or waist and hip circumference. In addition, no associations were found within subgroups of adult BMI (data not shown).

In analyses confined to hysterectomy-confirmed cases only, overall findings for anthropometric variables were similar to those in the combined group of cases (Table 3). The IRRs for BMI were larger than those derived from analyses among all cases, but the same inverse J-shaped pattern was observed. The IRRs for weight gain were stronger than the overall analyses. Because over 80% of hysterectomy-confirmed cases were parous, small numbers precluded the assessment of interaction.

TABLE 3.

Incidence Rates per 1000 Person-Years and Rate Ratios for Uterine Leiomyomata Confirmed by Hysterectomy According to Measures of Body Size and Body Fat Distribution

Anthropometric Variable No. of Cases Person-Years Crude IR Multivariate IRR (95% CI)*
BMI, current (kg/m2)
 <20.0 3 4033 0.7 1.00
 20.0–22.4 22 10,297 2.1 2.22 (0.66–7.45)
 22.5–24.9 44 13,297 3.3 2.90 (0.90–9.37)
 25.0–27.4 54 12,606 4.3 3.20 (1.00–10.29)
 27.5–29.9 42 8085 5.2 3.73 (1.15–12.09)
 30.0–32.4 37 6778 5.5 3.73 (1.14–12.17)
 32.5+ 59 15,250 3.9 2.67 (0.83–8.57)
BMI at age 18 (kg/m2)
 <18.5 52 12,500 4.2 1.00
 18.5–19.9 54 13,877 3.9 1.02 (0.69–1.49)
 20.0–22.4 87 21,104 4.1 1.13 (0.79–1.60)
 22.5–24.9 41 10,899 3.8 1.08 (0.71–1.64)
 25.0–27.4 15 5884 2.6 0.75 (0.42–1.34)
 27.5–29.9 6 2469 2.4 0.76 (0.32–1.78)
 30.0+ 6 3613 1.7 0.58 (0.24–1.35)
Weight gain since age 18 (kg)
 <5 19 12,900 1.5 1.00
 5–9 21 10,994 1.9 1.06 (0.57–1.97)
 10–14 48 12,021 4.0 1.93 (1.13–3.31)
 15–24 83 18,016 4.6 1.79 (1.08–2.97)
 25+ 90 16,414 5.5 1.84 (1.11–3.05)
Height (feet and inches)
 ≤5′2″ 47 12,709 3.7 1.00
 5′3″–5′4″ 60 17,721 3.4 0.95 (0.65–1.40)
 5′5″–5′6″ 78 18,872 4.1 1.19 (0.83–1.71)
 5′7″–5′8″ 53 13,397 4.0 1.26 (0.85–1.87)
 5′9″+ 23 7647 3.0 1.07 (0.64–1.77)
Waist circumference (inches)
 < 27 27 10,317 2.6 1.00
 27–29 37 14,146 2.6 0.73 (0.44–1.21)
 30–32 64 12,951 4.9 1.02 (0.62–1.67)
 33–35 38 8,182 4.6 0.85 (0.48–1.49)
 36+ 54 12,938 4.2 0.74 (0.41–1.34)
Hip circumference (inches)
 <36 23 10,226 2.2 1.00
 36–37 29 10,198 2.8 1.05 (0.60–1.83)
 38–40 66 14,869 4.4 1.21 (0.73–1.99)
 41–44 62 12,779 4.8 1.15 (0.67–1.98)
 45+ 40 10,463 3.8 0.92 (0.50–1.71)
Waist-to-hip ratio
 <0.71 39 11,838 3.3 1.00
 0.71–0.75 38 11,611 3.3 0.97 (0.62–1.51)
 0.76–0.79 50 11,993 4.2 1.09 (0.71–1.66)
 0.80–0.85 53 11,521 4.6 1.17 (0.77–1.78)
 0.86+ 40 11,571 3.5 0.83 (0.52–1.31)
*

Adjusted for age (1-yr intervals), time period (1997–1999 vs. 1999–2001), age at menarche (years), parity (number of births), age at first birth (years), years since last birth (linear term + 2 spline terms), ever use of oral contraceptives, education (≤12, 13–15, 16, 17+), living in the West, current alcohol consumption (<1, 1–6, 7+ per week), and smoking (never, former, current). Models of waist, hip, and waist-to-hip ratio measures are further adjusted for BMI in 1995 (<20, 20–24, 25–29, 30+).

Reference category.

Limited to 17,876 women with complete data on waist and hip circumference in 1995.

The overrepresentation of hysterectomy-confirmed cases among parous cases (19%) relative to nulliparous cases (5%) could have contributed to the observed parity interaction because associations were stronger in hysterectomy-confirmed cases. However, when we repeated the analyses among ultrasound-confirmed cases only (data not shown), the parity interaction with BMI and weight gain remained (P values = 0.01 and 0.005, respectively). The parity interaction also persisted within subgroups of age (<35 vs. 35+).

Because obese women were less likely than women of normal weight to report a recent Papanicolaou smear (Table 1), a marker of pelvic examination, we restricted analyses to the 90% of women who reported this practice. None of the results changed materially. In addition, results were similar when cases confirmed by pelvic examination (N = 387) were included as part of the outcome definition, censored at the time of diagnosis, or excluded at baseline. Finally, we found no evidence of effect modification by age, education, smoking, and geographic region, risk factors by which study participants may differ from other U.S. black women.

DISCUSSION

The present study is the largest prospective examination of anthropometric risk factors for uterine leiomyomata in U.S. black women. Overall findings for BMI and risk of uterine leiomyomata showed an inverse J-shaped pattern, with elevated IRRs for all categories of BMI above 20.0 kg/m2 and a peak incidence associated with a BMI category of 27.5–29.9 kg/m2. These results are consistent with previous studies that found a positive13,15,16 or inverse J-shaped association,14,17 but not with 3 other studies that found no association,1820 including one that stratified by race.20

The Nurses’ Health Study II, which has similar methodology to our study but includes >95% white women, observed similar associations for BMI.15 Multivariate IRRs increased with increasing BMI categories until reaching a peak at BMI 28.0–29.9 kg/m2, after which the risk decreased slightly.15 If BMI <20.0 kg/m2 were the reference category, the resulting IRR would have been 1.51, which is similar to the peak IRR observed in our data (1.47 for BMI = 27.5–29.9 kg/m2); however, the difference in risk between the normal and overweight BMI categories was less pronounced in our study than in the Nurses’ Health Study II. Like in the Nurses’ Health Study II, we found stronger associations among hysterectomy-confirmed cases. These data suggest that higher BMI might be associated with greater symptomatology. We remain cautious about the interpretation of results for hysterectomy-confirmed cases because numbers are small and the IRRs are more likely to reflect bias.7

The inverse J-shaped pattern for BMI and risk of uterine leiomyomata was present within parity subgroups and remained evident after the exclusion of nulliparous women who reported infertility, women who had a livebirth in a subsequent time interval, and women without a recent Papanicolaou smear. The observed pattern might be a real biologic phenomenon explained by decreased menstrual cycling among excessively thin and obese women compared with normal-weight women.37 A decrease in menstrual cyclicity may reduce risk of uterine leiomyomata by lowering levels of circulating estrogens and progesterone. Conversely, the observed pattern could reflect a detection bias if, for example, clinicians had greater difficulty detecting tumors by pelvic examination in obese women.

Our data suggest that the influence of elevated adult BMI and weight gain is greater among parous than nulliparous women. Epidemiologic studies show that parous women are at lower risk of uterine leiomyomata than nulliparous women, which may be the result of the long-term parity-related reduction in hormones associated with myoma growth such as estradiol and prolactin.38,39 Absolute incidence rates were higher in nulliparous women than in parous women, but only among women with normal or low BMI (or <25-kg weight gain), suggesting that overweight or obesity may dampen the protective effect of parity.31 The greater relative increase in exposure to endogenous hormones might explain how parity modifies the effect of BMI. For example, estrogens derived from adipose tissue may have a larger impact on parous women because their mean endogenous estrogen levels are significantly lower than those of nulliparous women.39

Differential exclusions could have created the appearance of interaction by parity in the relationship between BMI/weight gain and uterine leiomyomata. More than 10,000 women with a previous diagnosis of uterine leiomyomata were excluded before baseline. Although the current standard of clinical detection is transvaginal ultrasound, prior diagnoses could have depended on a wide array of diagnostic techniques with lower sensitivity in obese women (eg, pelvic examination or transabdominal ultrasound). Before baseline, most parous women will have had a pregnancy ultrasound during which tumors, if present, could have been identified. However, if this prestudy pregnancy screening were more effective in lean women, the study population at baseline could have disproportionately included obese women with undetected tumors. Consequently, transvaginal ultrasound might have picked up these undetected tumors in our study and overestimated the effect of obesity among parous women. Therefore, the observed parity interaction warrants confirmation in future studies.

Although height is associated with higher follicular-phase plasma estradiol levels in premenopausal women,8 we found no evidence of an association between height and uterine leiomyomata, consistent with findings from the Nurses’ Health Study II.15 Likewise, the null association found for BMI at age 18 agrees with Nurses’ Health Study II results.15

The influence of body fat distribution on risk of uterine leiomyomata has not been previously evaluated. Several studies have documented that central obesity is greater for black women than white women40 and is positively associated with age40 and parity.33 Neither waist circumference nor waist-to-hip ratio was associated with risk of uterine leiomyomata in the present study. Although our validation data showed that lean women reported waist-to-hip ratio with greater accuracy than obese women (Pearson correlation: 0.52 vs. 0.23), null associations were found in both groups. A combination of several counteracting effects could explain the lack of association. Although there is evidence that women with greater upper body obesity have decreased sex hormone-binding globulin levels,9,24 altered estrogen metabolism,24 and hyperinsulinemia,25,26 factors that may promote tumor development, there is also evidence that upper body obesity is associated with anovulation,25 which may reduce the risk of uterine leiomyomata.31

Validation data on weight and height showed strong correlations between self-reported and technician measurements. Correlations were lower for waist circumference, hip circumference, and waist-to-hip ratio. Because anthropometric data were collected before the diagnosis and confirmation of uterine leiomyomata, error in self-reported anthropometric measures was likely nondifferential. When there are several categories of exposure, nondifferential misclassification can bias results toward or away from the null.30

Study participants were not systematically screened for uterine leiomyomata. As a result of the high cumulative incidence of these tumors and their tendency to be asymptomatic,3 true cases may have been misclassified as noncases. In a study that screened randomly selected women age 35–49 years from an urban health plan, 59% of premenopausal black women reporting no previous diagnosis of uterine leiomyomata showed ultrasound evidence of the condition,3 although many of the tumors were not clinically significant. Because specificity of disease classification was high in our study, as indicated by the low proportion of false-positive diagnoses (4%), we expect little bias resulting from nondifferential misclassification.30 Bias resulting from differential disease misclassification is more likely because BMI can affect healthcare use, which can influence the probability of fibroid detection. Although lower levels of screening among obese women (Table 1) could have produced a downward bias of the BMI association, results were similar when we restricted the analytic sample to the 90% of women who reported a recent Papanicolaou smear.

High follow up in our study reduces the potential for selection bias. However, subscribers to Essence magazine may differ from the general population of U.S. black women in ways that may affect the generalizability of our findings to the larger population. The distributions of BMI and parity in our cohort were similar to those documented in nationally representative studies of reproductive-aged black women.27,41 Moreover, we did not find any effect modification by education, smoking, or geographic region on the main associations. Therefore, we expect the present findings to extend to other U.S. black women.

The associations of uterine leiomyomata with BMI and weight gain in the present study are too complex to support simple recommendations for the prevention of uterine leiomyomata. Women in the normal range of BMI might decrease their risk with weight loss, but the opposite effect might hold true for obese women. The consistent finding of a reduced risk among the leanest women (BMI <20 kg/m2) supports the hypothesis that uterine leiomyomata are hormone-dependent tumors.5 A variety of hormones may be involved in this modification of risk, given that thin or anorexic women are found to have higher levels of sex hormone-binding globulin,8,9 decreased prolactin secretion,42 and increased hydroxylation of estrone to catechol estrogens11—all of which may create an endogenous hormonal milieu with lower susceptibility to uterine leiomyomata.

Acknowledgments

We gratefully acknowledge the assistance of Lynn Marshall, Ellen Hertzmark, and Sue Malspeis in the writing of this paper. Special thanks to the study participants and staff of the Black Women’s Health Study.

Footnotes

This work was supported by National Cancer Institute grant CA58420.

References

  • 1.Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990–1997. Obstet Gynecol. 2002;99:229–234. doi: 10.1016/s0029-7844(01)01723-9. [DOI] [PubMed] [Google Scholar]
  • 2.Kjerulff KH, Langenberg P, Seidman JD, et al. Uterine leiomyomas: racial differences in severity, symptoms, and age at diagnosis. J Reprod Med. 1996;41:483–490. [PubMed] [Google Scholar]
  • 3.Baird DD, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188:100–107. doi: 10.1067/mob.2003.99. [DOI] [PubMed] [Google Scholar]
  • 4.Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997;90:967–973. doi: 10.1016/s0029-7844(97)00534-6. [DOI] [PubMed] [Google Scholar]
  • 5.Andersen J. Growth factors and cytokines in uterine leiomyomas. Semin Reprod Endocrinol. 1996;14:269–282. doi: 10.1055/s-2007-1016336. [DOI] [PubMed] [Google Scholar]
  • 6.Willett WC. Anthropometric measures and body composition. In: Willett WC, editor. Nutritional Epidemiology. 2. New York: Oxford University Press; 1998. pp. 244–272. [Google Scholar]
  • 7.Schwartz SM, Marshall LM, Baird DD. Epidemiologic contributions to understanding the etiology of uterine leiomyomata. Environ Health Perspect. 2000;108:821–827. doi: 10.1289/ehp.00108s5821. [DOI] [PubMed] [Google Scholar]
  • 8.Dorgan JF, Reichman ME, Judd JT, et al. The relation of body size to plasma levels of estrogens and androgens in premenopausal women (Maryland, United States) Cancer Causes Control. 1995;6:3–8. doi: 10.1007/BF00051674. [DOI] [PubMed] [Google Scholar]
  • 9.Verkasalo PK, Thomas HV, Appleby PN, et al. Circulating levels of sex hormones and their relation to risk factors for breast cancer: a cross-sectional study in 1092 pre- and postmenopausal women (United Kingdom) Cancer Causes Control. 2001;12:47–59. doi: 10.1023/a:1008929714862. [DOI] [PubMed] [Google Scholar]
  • 10.Grenman S, Ronnemaa T, Irjala K, et al. Sex steroid, gonadotropin, cortisol and prolactin levels in healthy, massively obese women: correlation with abdominal fat cell size and effect of weight reduction. J Clin Endocrinol Metab. 1986;63:1257–1261. doi: 10.1210/jcem-63-6-1257. [DOI] [PubMed] [Google Scholar]
  • 11.Fishman J, Boyar RM, Hellman L. Influence of body weight on estradiol metabolism in young women. J Clin Endocrinol Metab. 1975;41:989–991. doi: 10.1210/jcem-41-5-989. [DOI] [PubMed] [Google Scholar]
  • 12.Schneider J, Bradlow HL, Strain G, et al. Effects of obesity on estradiol metabolism: decreased formation of nonuterotropic metabolites. J Clin Endocrinol Metab. 1983;56:973–978. doi: 10.1210/jcem-56-5-973. [DOI] [PubMed] [Google Scholar]
  • 13.Ross RK, Pike MC, Vessey MP, et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J Clin Res Ed. 1986;293:359–362. doi: 10.1136/bmj.293.6543.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Lumbiganon P, Rugpao S, Phandhu-Fung S, et al. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case–control study. Br J Obstet Gynaecol. 1996;103:909–914. doi: 10.1111/j.1471-0528.1996.tb09911.x. [DOI] [PubMed] [Google Scholar]
  • 15.Marshall LM, Spiegelman D, Manson JE, et al. Risk of uterine leiomyomata among premenopausal women in relation to body size and cigarette smoking. Epidemiology. 1998;9:511–517. [PubMed] [Google Scholar]
  • 16.Faerstein E, Szklo M, Rosenshein N. Risk factors for uterine leiomyoma: a practice-based case-control study. I. African-American heritage, reproductive history, body size, and smoking. Am J Epidemiol. 2001;153:1–10. doi: 10.1093/aje/153.1.1. [DOI] [PubMed] [Google Scholar]
  • 17.Parazzini F, Negri E, La Vecchia C, et al. Reproductive factors and risk of uterine fibroids. Epidemiology. 1996;7:440–442. doi: 10.1097/00001648-199607000-00018. [DOI] [PubMed] [Google Scholar]
  • 18.Romieu I, Walker AM, Jick S. Determinants of uterine fibroids. Post Mark Surveill. 1991;5:119–133. [Google Scholar]
  • 19.Samadi AR, Lee NC, Flanders WD, et al. Risk factors for self-reported uterine fibroids: a case–control study. Am J Public Health. 1996;86:858–862. doi: 10.2105/ajph.86.6.858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Chen CR, Buck GM, Courey NG, et al. Risk factors for uterine fibroids among women undergoing tubal sterilization. Am J Epidemiol. 2001;153:20–26. doi: 10.1093/aje/153.1.20. [DOI] [PubMed] [Google Scholar]
  • 21.Haiman CA, Pike MC, Bernstein L, et al. Ethnic differences in ovulatory function in nulliparous women. Br J Cancer. 2002;86:367–371. doi: 10.1038/sj.bjc.6600098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Woods MN, Barnett JB, Spiegelman D, et al. Hormone levels during dietary changes in premenopausal African-American women. J Natl Cancer Inst. 1996;88:1369–1374. doi: 10.1093/jnci/88.19.1369. [DOI] [PubMed] [Google Scholar]
  • 23.Manson JM, Sammel MD, Freeman EW, et al. Racial differences in sex hormone levels in women approaching the transition to menopause. Fertil Steril. 2001;75:297–304. doi: 10.1016/s0015-0282(00)01723-4. [DOI] [PubMed] [Google Scholar]
  • 24.Kirschner MA, Samojlik E, Drejka M, et al. Androgen–estrogen metabolism in women with upper body versus lower body obesity. J Clin Endocrinol Metab. 1990;70:473. doi: 10.1210/jcem-70-2-473. [DOI] [PubMed] [Google Scholar]
  • 25.Moran C, Hernandez E, Ruiz JE, et al. Upper body obesity and hyperinsulinemia are associated with anovulation. Gynecol Obstet Invest. 1999;47:1–5. doi: 10.1159/000010052. [DOI] [PubMed] [Google Scholar]
  • 26.Falkner B, Sherif K, Sumner A, et al. Hyperinsulinemia and sex hormones in young adult African Americans. Metabolism. 1999;48:107–112. doi: 10.1016/s0026-0495(99)90018-5. [DOI] [PubMed] [Google Scholar]
  • 27.Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002:288. doi: 10.1001/jama.288.14.1723. [DOI] [PubMed] [Google Scholar]
  • 28.Rosenberg L, Adams-Campbell LL, Palmer JR. The Black Women’s Health Study: a follow-up study for causes and preventions of illness. J Am Med Womens Assoc. 1995;50:56–58. [PubMed] [Google Scholar]
  • 29.Dueholm M, Lundorf E, Hansen ES, et al. Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas. Am J Obstet Gynecol. 2002;186:409–415. doi: 10.1067/mob.2002.121725. [DOI] [PubMed] [Google Scholar]
  • 30.Rothman K, Greenland S. Modern Epidemiology. Philadelphia: Lippincott-Raven; 1998. [Google Scholar]
  • 31.Wise LA, Palmer JR, Harlow BL, et al. Reproductive factors, hormonal contraception and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol. 2004;159:113–123. doi: 10.1093/aje/kwh016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Rosenberg L, Palmer JR, Wise LA, et al. A prospective study of the effect of childbearing on weight gain in African-American women. Obesity Res. 2003;11:1526–1535. doi: 10.1038/oby.2003.204. [DOI] [PubMed] [Google Scholar]
  • 33.Smith DE, Lewis CE, Caverny JL, et al. Longitudinal changes in adiposity associated with pregnancy: the CARDIA Study. JAMA. 1994;271:1747–1751. [PubMed] [Google Scholar]
  • 34.World Health Organisation. Physical Status: The Use and Interpretation of Anthropometry. Geneva: World Health Organisation; 1995. [Google Scholar]
  • 35.Wise LA, Palmer JR, Stewart EA, et al. Age-specific incidence rates for self-reported uterine leiomyomata in the Black Women’s Health Study. Obstet Gynecol. 2005;105:563–568. doi: 10.1097/01.AOG.0000154161.03418.e3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Wise LA, Palmer JR, Harlow BL, et al. Risk of uterine leiomyomata in relation to tobacco, alcohol and caffeine consumption in the Black Women’s Health Study. Hum Reprod. 2004;19:1746–1754. doi: 10.1093/humrep/deh309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Rich-Edwards JW, Spiegelman D, Garland M, et al. Physical activity, body mass index, and ovulatory disorder infertility. Epidemiology. 2002;13:184–190. doi: 10.1097/00001648-200203000-00013. [DOI] [PubMed] [Google Scholar]
  • 38.Musey VC, Collins DC, Musey PI, et al. Long-term effect of a first pregnancy on the secretion of prolactin. N Engl J Med. 1987;316:229–234. doi: 10.1056/NEJM198701293160501. [DOI] [PubMed] [Google Scholar]
  • 39.Dorgan JF, Reichman ME, Judd JT, et al. Relationships of age and reproductive characteristics with plasma estrogen and androgens in premenopausal women. Cancer Epidemiol Biomarkers Prev. 1995;4:381–386. [PubMed] [Google Scholar]
  • 40.Burke GL, Jacobs DR, Sprafka PJ, et al. Obesity and overweight in young adults: the CARDIA study. Prev Med. 1990;19:476–488. doi: 10.1016/0091-7435(90)90045-l. [DOI] [PubMed] [Google Scholar]
  • 41.Abma JC, Chandra A, Mosher WD, et al. Fertility, family planning, and women’s health: new data from the 1995 National Survey of Family Growth. Vital Health Stat. 1997:23. [PubMed] [Google Scholar]
  • 42.Zumoff B. Influence of obesity and malnutrition on the metabolism of some cancer-related hormones. Cancer Res. 1981;41:3805–3807. [PubMed] [Google Scholar]

RESOURCES